menu
    • menu
    [{"orgOrder":0,"company":"Dipharma","sponsor":"Analog Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Nitisinone","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Dipharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Dipharma \/ Dipharma","highestDevelopmentStatusID":"12","companyTruncated":"Dipharma \/ Dipharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Dipharma

    Menu

    Dipharma

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Dipharma

                            Italy arrow
                            Antibody Engineering
                            Not Confirmed

                            Dipharma

                            Italy arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nitisinone

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved

                            Recipient : Analog Pharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Analog Pharma and Dipharma Announce US FDA Approval of Abbreviated New Drug Application (ANDA) of 20 mg Generi...

                            Details : Orfadin (nitisinone) is a hydroxy-phenylpyruvate dioxygenase inhibitor indicated for the treatment of adult and pediatric patients with hereditary tyrosinemia type 1.

                            Brand Name : Orfadin-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 31, 2023

                            Lead Product(s) : Nitisinone

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved

                            Recipient : Analog Pharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth